CClinicalTrials.gg
CompletedNCT05277038Updated Nov 18, 2022

Clonidine is Better Than Zopiclone for Insomnia Treatment in Chronic Pain Patients

An observational study in Insomnia Chronic and Pain, Chronic, sponsored by Salem Anaesthesia Pain Clinic. Completed at 1 site in Canada. Open to participants aged 20 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Salem Anaesthesia Pain Clinic · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
150
Ages
20 Years to 99 Years
Sex
All
01

Study summary

A prospective observational crossover study of 160 consenting adult patients who underwent pain management. For insomnia treatment, each patient ingested different prescribed doses of Zopiclone or Clonidine on alternate nights. Each patient used a special validated sleep diary to collect data including pain score, sleep scores, sleep duration, sleep medication dose, and adverse effects. Each patient completed the diary for 3 continuous weeks. Pain was measured using the numeric pain rating scale. Sleep score was measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points was considered significant.

Read the detailed description

Objectives: Chronic pain is associated with insomnia. The objective of this clinical study is to compare the efficacy and safety of different prescribed doses of Zopiclone and Clonidine; for the management of insomnia in patients with chronic pain.

Methods: A prospective observational crossover study of 160 consenting adult patients who underwent pain management. For insomnia treatment, each patient ingested different prescribed doses of Zopiclone or Clonidine on alternate nights. Each patient used a special validated sleep diary to collect data including pain score, sleep scores, sleep duration, sleep medication dose, and adverse effects. Each patient completed the diary for 3 continuous weeks. Pain was measured using the numeric pain rating scale. Sleep score was measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points was considered significant. Data were analyzed with IBM® SPSS® Statistics 25 (IBM Corp, Armonk, NY); using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 was considered significant.

02

Conditions studied

  • Insomnia Chronic
  • Pain, Chronic

Keywords

  • sedative
  • hypnotic
03

In context

Sleep Initiation and Maintenance Disorders

1,856 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 594 are open to participants now.

This study's enrollment of 150 is above the median of 128 across 191 observational studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Salem Anaesthesia Pain Clinic is the lead sponsor of 19 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

A cohort of consecutive adult patients who underwent pain management at a Canadian pain clinic

Inclusion criteria

  • adult chronic pain patients
  • good treatment compliance
  • severe chronic insomnia
  • failure of non-pharmacologic sleep therapy
  • regular zopiclone therapy for 3 months or more
  • regular sleep diary
  • regular pain diary
  • informed consent for diary review
  • consent for clinical record quality assurance review.

Exclusion criteria

Exclusion Criteria:

  • obstructive sleep apnoea
  • body mass index (BMI) ≥40
  • organ insufficiency
  • cognitive disorder
  • inability to provide consent
  • major neuropsychiatric disorder
  • unreliable diary
  • cannabis use
  • regular alcohol intake
  • stimulant use
  • substance abuse
  • poor treatment compliance
  • high dose opioid
  • gabapentinoid use
  • sedative use
  • mild insomina
  • irregular zopiclone intake
  • regular zopiclone therapy for less than 3 months
  • previous adverse/allergic reactions to clonidine or zopiclone.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
150 participants (actual)
Target follow-up
3 Weeks
Patient registry
Yes

Groups and cohorts

  • Clonidine vs Zopiclone for insomnia

    Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.

    Drug: Clonidine 0.1mg pill · Drug: Clonidine 0.2mg pill · Drug: Zopiclone 3.75mg pill · Drug: Zopiclone 7.5mg pill

Interventions

  • DrugClonidine 0.1mg pill

    Routine prescription for insomnia

    Also known as: Clonidine 0.1mg tablet

  • DrugClonidine 0.2mg pill

    Routine prescription for insomnia

    Also known as: Clonidine 0.2mg tablet

  • DrugZopiclone 3.75mg pill

    Routine prescription for insomnia

    Also known as: Zopiclone 3.75mg tablet

  • DrugZopiclone 7.5mg pill

    Routine prescription for insomnia

    Also known as: Zopiclone 7.5mg tablet

06

What researchers measure

Primary outcomes

  1. Sleep quality score, objective measurement using the validated Likert sleep scale

    Sleep quality score, using the Likert sleep scale of 0 to 10, low scores indicate poor sleep, high scores indicate better sleep

    Time frame: 3 weeks

Secondary outcomes

  1. Pain score, objective measurement using the validated Numeric Pain Rating scale

    Pain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain

    Time frame: 3 weeks

07

Study locations

1 site
  • Salem Anaesthesia Pain Clinic
    Surrey, British Columbia V3S 7J1, Canada
08

References and documents

Publications

  • Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol. 1997 Apr;244(4 Suppl 1):S18-22. doi: 10.1007/BF03160567. PubMed 9112585 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05277038
Lead sponsor
Salem Anaesthesia Pain Clinic
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Mar 1, 2022
Primary completion
Nov 5, 2022
Completion
Nov 5, 2022
Last update
Nov 18, 2022

Study contacts

Olu Bamgbade, MD, FRCPC
principal investigator · Salem Anaesthesia Pain Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion